Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 3/20 | 0.44 |
| ▸ | TREH | O43280 | 1/20 | 0.37 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.34 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.34 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.32 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25871286 | 1.00 | LGALS3 (0.44) | LGALS3TREHLGALS1LGALS9LGALS8 | |
| SCHEMBL13295915 | 1.00 | LGALS3 (0.44) | LGALS3TREHLGALS1LGALS9LGALS8 | |
| SCHEMBL25672308 | 1.00 | LGALS3 (0.44) | LGALS3TREHLGALS1LGALS9LGALS8 | |
| SCHEMBL14613514 | 1.00 | LGALS3 (0.44) | LGALS3TREHLGALS1LGALS9LGALS8 | |
| SCHEMBL15966159 | 1.00 | LGALS3 (0.44) | LGALS3TREHLGALS1LGALS9LGALS8 | |
| SCHEMBL23705209 | 1.00 | LGALS3 (0.44) | LGALS3TREHLGALS1LGALS9LGALS8 | |
| SCHEMBL16155530 | 1.00 | LGALS3 (0.44) | LGALS3TREHLGALS1LGALS9LGALS8 | |
| SCHEMBL13295952 | 1.00 | LGALS3 (0.44) | LGALS3TREHLGALS1LGALS9LGALS8 | |
| SCHEMBL13344935 | 1.00 | LGALS3 (0.44) | LGALS3TREHLGALS1LGALS9LGALS8 | |
| SCHEMBL12929237 | 0.93 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230346951-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | YALE UNIVERSITY | 2023-11-02 | — | — | US | disclosed |
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | UNIV YALE (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | UNIV YALE (US) | 2023-07-27 | — | — | US | disclosed |
| WO-2023288033-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | LGALS3 240/4885TREH 2371/4885LGALS1 114/4885 |
| US-20230346951-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | ASGR1, MSR1, LDLR | LGALS3 304/4885TREH 3300/4885LGALS1 73/4885 |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | ASGR1, LDLR, FCGR2A | LGALS3 435/4885TREH 4061/4885LGALS1 126/4885 |
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | ASGR1, LAMP2, FCGR2A | LGALS3 264/4885TREH 2467/4885LGALS1 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.